RHOA and breast carcinoma: Our data demonstrate that NRF2 binds the ERR1 promoter region as a silencer and inhibits the expression of ERR1, which further stabilizes RhoA protein levels, leading to cytoskeletal changes that underlie cell proliferation and metastasis of breast cancer cells.